Skip to main content

Table 3 Genes linked to promoter regions associated with the top DMFs

From: Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions

Gene ID

CpGs

Control %

Patient %

Difference

P value

F test value

LOC339166

11

75

33

− 42

6.85 × 10–3

F(1,14) = 10.03

LOC339166

8

80

46

− 34

3.78 × 10–3

F(1,14) = 12.02

ZNF876P

15

53

31

− 22

8.28 × 10–3

F(1,13) = 9.68

RAB20

5

42

25

− 17

5.20 × 10–3

F(1,16) = 10.46

NUDT14

3

38

21

− 17

5.30 × 10–3

F(1,14) = 10.87

MIR138-2

5

78

62

− 16

2.23 × 10–2

F(1,14) = 6.59

ZNF714

6

12

42

+ 30

1.12 × 10–2

F(1,16) = 8.22

C8orf31

3

43

64

+ 21

4.75 × 10–2

F(1,13) = 4.79

PAX8-AS1

7

65

83

+ 18

3.07 × 10–2

F(1,15) = 5.69

CCDC144NL

8

58

75

+ 17

3.36 × 10–2

F(1,16) = 5.41

LINC00923

4

60

76

+ 16

6.79 × 10–3

F(1,17) = 9.49

WNK2

17

38

54

+ 16

1.12 × 10–2

F(1,16) = 8.22

  1. For each Gene ID, there is the corresponding number of CpGs within the identifying fragment, the average percentage methylation for the control subjects and ME/CFS patients, with differences (− is hypo-methylated, + is hyper-methylated). P values and F test values (degrees of freedom in brackets) are shown